DSIP Peptide Dosage: Sleep Protocols

DSIP promotes synchronization of thalamic and cortical neurons into slow oscillation patterns. It modulates GABAergic and glutamatergic signaling in the regions that generate sleep spindles and delta waves. An early clinical study in chronic insomnia patients showed increased delta-wave power on overnight EEG recordings after DSIP administration (Schneider-Helmert & Schoenenberger, Eur Neurol, 1983; PMID 6653901).

Deep sleep is when your body does its most critical repair work. Growth hormone secretion peaks during delta-wave episodes, immune cell production surges, and the brain's glymphatic system clears metabolic waste at 10 to 20 times the waking rate.

Elevated evening cortisol is one of the most common reasons people cannot fall asleep. The hypothalamic-pituitary-adrenal (HPA) axis is supposed to wind down at night, but chronic stress keeps it firing. DSIP directly modulates this axis.

A study in human volunteers demonstrated that DSIP administration normalized cortisol secretion patterns and reduced stress-related sleep disruption (Polleri et al., Psychopharmacology, 1985; PMID 3923513). DSIP does not suppress cortisol outright. You still need morning cortisol for alertness. It restores the natural diurnal curve: high in the morning, low at night.

The largest growth hormone pulse of the day occurs during the first deep sleep episode, typically 60 to 90 minutes after falling asleep. By increasing time spent in delta-wave sleep, DSIP amplifies this natural GH surge.

For users seeking maximum overnight recovery, stacking DSIP with Ipamorelin creates synergy. DSIP deepens the sleep; Ipamorelin directly stimulates the pituitary to release more GH during that deeper sleep. Two mechanisms, one window. Use the Peptide Stack Calculator to map the protocol.

Dose: 100 mcg subcutaneously, once nightly Timing: 30 to 60 minutes before bed Cycle: 2 weeks on, 2 weeks off Best for: First-time DSIP users, mild sleep difficulties, jet lag

Start here. Most users notice improved sleep quality within the first 2 to 3 nights: falling asleep faster, fewer mid-night awakenings, and a distinct sense of "deeper" rest upon waking. A clinical study using DSIP in chronic insomnia patients reported significant improvements in sleep onset latency and subjective sleep quality at doses as low as 25 nmol (approximately 90 mcg) (Schneider-Helmert & Schoenenberger, 1983; PMID 6653901).

If 100 mcg produces noticeable improvement, stay at this dose. More is not automatically better with DSIP. The peptide triggers a cascade; once the cascade is triggered, additional peptide adds diminishing returns.

Dose: 200 mcg subcutaneously, once nightly Timing: 30 to 60 minutes before bed Cycle: 3 to 4 weeks on, 2 weeks off Best for: Chronic poor sleep, shift workers, high-stress periods

This is the most widely used protocol. The additional 100 mcg over the beginner dose deepens the delta-wave response for users who found 100 mcg insufficient or whose sleep disruption stems from elevated cortisol.

Shift workers benefit particularly. DSIP does not force a circadian rhythm change, but it enhances the quality of whatever sleep window you have. A night-shift nurse sleeping from 8 a.m. to 3 p.m. can inject DSIP 30 minutes before that window and get more restorative sleep from fewer hours. For anxiety-driven insomnia, consider adding Selank intranasally 1 to 2 hours before the DSIP injection.

Dose: 300 mcg subcutaneously, once nightly Timing: 30 to 60 minutes before bed Cycle: 4 weeks on, 2 weeks off Best for: Severe insomnia, recovery from overtraining, high-cortisol states

The upper end of the dosing range. Reserve this for cases where 200 mcg produced partial but insufficient improvement. A study examining DSIP's neuroendocrine effects administered doses up to 300 mcg in human subjects without significant adverse effects (Kafi et al., Neuropsychobiology, 1979; PMID 514474).

At 300 mcg, morning drowsiness becomes more common. If you wake feeling groggy, reduce to 200 mcg. The grogginess typically clears within 20 to 30 minutes but can interfere with early-morning obligations.

Dose: 200 mcg DSIP + 200 mcg Ipamorelin Timing: Both injected 30 minutes before bed Cycle: 4 to 8 weeks on, 2 to 4 weeks off Best for: Athletes, recovery-focused users, anti-aging protocols

This is the sleep-and-recovery stack. DSIP extends delta-wave time; Ipamorelin releases a GH bolus during that extended deep sleep window. The combination targets two mechanisms with one bedtime injection session.

Draw each peptide into separate syringes. Do not mix them in the same vial; stability data for this combination does not exist. Inject both subcutaneously in the abdomen, rotating sites. Check compatibility before combining peptides using the Peptide Interaction Checker.

For users who also want circadian rhythm support, a low dose of Epitalon (5 mg every other day for 10 to 20 days) can be layered on top. Epitalon regulates pineal melatonin production through a separate pathway.

During off-periods, sleep quality often remains improved for the first 5 to 7 days. Some users bridge the gap with low-dose melatonin (0.3 to 0.5 mg) or Selank for anxiety-related sleep maintenance.

For a 2 mg vial (most common):

Add 1 mL of bacteriostatic water. This produces a concentration of 2 mg/mL, which equals 2,000 mcg/mL. On a U-100 insulin syringe:

For a 5 mg vial:

Add 2.5 mL of bacteriostatic water for the same 2 mg/mL concentration. Or add 1 mL for a more concentrated 5 mg/mL solution (useful if you prefer smaller injection volumes).

Steps: 1. Bring the vial and bacteriostatic water to room temperature. 2. Wipe both rubber stoppers with an alcohol swab. 3. Draw the bacteriostatic water with an insulin syringe. 4. Insert the needle into the DSIP vial at an angle. Let the water trickle down the glass wall. Do not squirt directly onto the powder. 5. Do not shake. Swirl gently or let the vial sit until the powder dissolves. The solution should be clear. 6. Refrigerate immediately. Use within 28 days.

For exact measurements with any vial size, use the Peptide Reconstitution Calculator. For guidance on water types, see bacteriostatic water vs sterile water.

Route: Subcutaneous (into the fat layer beneath the skin) Syringe: Insulin syringe, 29 to 31 gauge, 0.5 mL or 1 mL Sites: Abdomen (2 inches from the navel), outer thigh, or upper arm

Pinch a fold of skin at the injection site. Insert the needle at a 45-degree angle. Push the plunger slowly and steadily. Wait 3 to 5 seconds before withdrawing. Rotate injection sites each night to prevent irritation and scar tissue.

Some users prefer intranasal administration for convenience. Nasal sprays avoid needles but deliver less predictable absorption, especially when nasal congestion is present. Subcutaneous injection remains the standard when consistent dosing matters. For a full injection walkthrough, see the peptide injection guide.

Reconstituted DSIP must be refrigerated at 2 to 8 degrees Celsius. Do not freeze reconstituted solution. Keep the vial upright and away from light.

Shelf life after reconstitution: approximately 28 days when stored properly. If the solution becomes cloudy, discolored, or contains particles, discard it. For detailed storage protocols for all peptides, see how to store peptides and how long reconstituted peptides last.

You inject 50 mcg thinking less is safer. This is below the threshold used in clinical studies. The signaling cascade may not fully initiate. You sleep the same as before, conclude DSIP does not work, and abandon the protocol.

The fix: Start at 100 mcg for at least 3 nights before judging effectiveness. The clinical literature begins at approximately 90 mcg (25 nmol). Going lower is untested territory.

You assume more peptide means deeper sleep and inject 500 mcg. The next morning, you wake groggy, disoriented, and with a dull headache that takes an hour to clear. This morning sedation effect has been reported at higher doses and can impair driving or early-morning work.

The fix: Cap your dose at 300 mcg. The dose-response curve flattens well before 500 mcg. Increasing beyond 300 mcg adds side effects without proportional sleep improvement. If 300 mcg is insufficient, the problem likely requires a different intervention, not more DSIP.

You add 2 mL to a 2 mg vial instead of 1 mL. Your concentration drops to 1 mg/mL. You draw 5 units thinking you have 100 mcg, but you actually inject 50 mcg. Half the intended dose, for the entire cycle.

The fix: Always verify your concentration math before the first injection. Write it down or use the Peptide Reconstitution Calculator. Double-check: vial content (mg) divided by water volume (mL) equals your concentration (mg/mL). Convert to mcg/mL by multiplying by 1,000.

Jet Lag: Inject at your destination's target bedtime, regardless of what your body clock says. A 3 to 5 day course upon arrival accelerates circadian adjustment.

Shift Work: Inject 30 to 60 minutes before your designated sleep window, whether that is 8 a.m. or 2 p.m. DSIP does not care about the clock. It promotes delta-wave sleep whenever sleep occurs.

Stacking with Ipamorelin: Inject both peptides at the same time, 30 minutes before bed. Ipamorelin's GH release aligns with the deep sleep window DSIP creates. Staggering the injections offers no proven advantage.

With Melatonin: If using low-dose melatonin (0.3 to 0.5 mg), take melatonin 60 to 90 minutes before bed, then DSIP at 30 minutes. Melatonin signals "time to sleep" to the circadian system; DSIP deepens the sleep that follows. They target different mechanisms and complement each other.

Schneider-Helmert & Schoenenberger (1983): Chronic insomnia patients received DSIP intravenously over 5 consecutive evenings. EEG recordings showed increased delta-wave power and improved subjective sleep quality. Sleep onset latency decreased. No significant adverse effects were observed (PMID 6653901).

Kafi et al. (1979): Healthy volunteers receiving DSIP showed measurable changes in sleep EEG architecture, with increased slow-wave sleep and altered sleep stage distribution. The effects persisted beyond the peptide's pharmacokinetic half-life, supporting the "trigger" hypothesis (PMID 514474).

Polleri et al. (1985): DSIP administration modulated cortisol and ACTH secretion in human subjects, demonstrating the peptide's interaction with the HPA axis. Cortisol rhythms shifted toward normalization in stressed subjects (PMID 3923513).

Larbig et al. (1984): DSIP showed analgesic properties in chronic pain patients, with effects mediated through opioid receptor interactions. Improved sleep was a secondary outcome in patients whose pain had been disrupting sleep (PMID 6281420).

The honesty matters. DSIP's clinical research has real gaps. Most human studies were conducted in the 1980s with small sample sizes (10 to 30 subjects). No large-scale, placebo-controlled, randomized trial has been published. The peptide never entered pharmaceutical development pipelines, so the kind of Phase III data that exists for sleeping pills does not exist for DSIP.

What the existing data shows: DSIP consistently increases delta-wave sleep on EEG, modulates cortisol, and improves subjective sleep quality. What it does not show: optimal dosing for different populations, long-term safety profiles, or comparative efficacy against modern sleep interventions. Users should weigh these limitations against the favorable safety data that does exist.

One of DSIP's more unexpected research applications involves opioid withdrawal. Studies in both animals and humans suggest DSIP modulates endogenous opioid peptide levels, stabilizing the beta-endorphin fluctuations that contribute to withdrawal symptoms (Dick et al., Eur J Pharmacol, 1984; PMID 6281420).

A clinical case series reported that DSIP administration during opioid detoxification reduced withdrawal severity and improved sleep quality in patients undergoing tapering protocols (Iyer et al., Neurosci Biobehav Rev, 1988; PMID 2555650). This application remains experimental and should only be considered under medical supervision.

Selank is an anxiolytic heptapeptide that modulates GABA and serotonin without sedation. For people whose insomnia stems from racing thoughts and evening anxiety, Selank addresses the cause while DSIP improves the sleep itself.

Protocol: Selank 250 to 500 mcg intranasally, 1 to 2 hours before bed. DSIP 200 mcg subcutaneously, 30 minutes before bed. Run both for 2 to 4 weeks, then cycle off together. Check compatibility at the Peptide Interaction Checker.

Injuries heal fastest during deep sleep. BPC-157 accelerates tissue repair through VEGF upregulation and angiogenesis. Stacking with DSIP creates a longer deep-sleep window for that healing to occur.

Protocol: DSIP 200 mcg subcutaneously before bed. BPC-157 250 to 500 mcg subcutaneously, either near the injury or in the abdomen, once daily. Both can be injected at the same pre-bed session. See the BPC-157 dosage guide for weight-based protocols and the peptide stacking guide for general combination principles.

Athletes lose sleep quality during heavy training blocks. Cortisol stays elevated from afternoon sessions. Muscle repair demands more deep sleep than the body is getting. DSIP addresses both problems: it normalizes evening cortisol and extends the delta-wave recovery window.

A practical protocol for training athletes: 200 mcg DSIP nightly during the 3 to 4 most intense training weeks of a mesocycle. Cycle off during deload weeks when sleep demand is lower. For peptide options focused on muscle performance, see peptides for bodybuilding.

Morning grogginess (10 to 15% of users at 200+ mcg): Usually resolves within 20 to 30 minutes of waking. More common at 300 mcg. Reduce dose if it persists beyond the third night.

Vivid dreams (15 to 25% of users): Altered sleep architecture changes dream content. Most users find this neutral or positive. Rarely, dreams become unpleasant enough to warrant dose reduction.

Mild headache upon waking (5 to 10%): Typically occurs during the first 2 to 3 nights and resolves spontaneously. Hydration before bed reduces incidence.

Injection site irritation (5%): Standard for any subcutaneous peptide. Rotate sites. See the peptide injection guide for technique refinement.

Do not use DSIP if you are taking benzodiazepines, barbiturates, or other CNS depressants without physician oversight. The additive effects on GABAergic signaling create unpredictable sedation depth.

Individuals with clinical depression should use DSIP cautiously. Altered sleep architecture can theoretically affect mood regulation. Monitor mood closely during the first cycle.

Pregnant or breastfeeding women should not use DSIP. No safety data exists for these populations.

DSIP may have mild hypotensive effects. People with uncontrolled low blood pressure should start at 100 mcg and monitor symptoms. For a broader view of peptide safety considerations, see the peptide safety guide.